Pleased as it is with strong half-time sales growth, management at paper-maker James Cropper has warned the second half is likely to be hit by rising prices of paper pulp and energy.
These creeping costs are projected mostly to affect the speciality papers division, which enjoyed 6% sales growth during the first half. Price increases have been scheduled to absorb some of the impact, but the next six months are expected to be roughly flat.
Another external influence on the company has been the weakness of the US dollar, which quashed most of the benefits of the internal investment at the converting division. Thus profits were only in line with last year despite sales rising 6%.
With half its sales made across the Pond, performance at Technical Fibre Products (TFP) was similarly dampened by the weak greenback: profits were flat despite 30% turnover growth within the division. During the half, TFP acquired two key suppliers for £0.5m because, explains finance director John Denman, ‘even though they’re small, they service either very important customers or potentially very large contracts’. This ‘potentially very large’ contract – assumed to be with defence specialist Northrop Grumman to provide a skin for stealth aircraft – is not likely to reach commercialisation until at least 2012.
Finally, the Paper Mill Shop retail arm lost a similar amount last year, despite growing revenues. Denman reckons management now have a better idea of their ideal market, and a restructuring of the company’s estate and offering is imminent.
House broker Brewin Dolphin forecasts that full-year earnings of 19.5p will grow almost 40% to 27.2p for 2009, reducing the forward earnings multiple from 12.3 to 8.8. Forewarned cost escalation will repel the cautious, but the shares look good value and could reward a punt.
Growth Company Investor subscribers have full access to all our AIM and small-cap share recommendations. To subscribe today with a half-price offer, and gain immediate access to all the recommendations, click here.
Market cap: £20.25m
PE Forecast: 12.3
Share price: 239p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.